(Q42607526)

3 November 2017

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma (English)

1 reference

3 November 2017

0 references

1 reference

William Berger

1

1 reference

3 November 2017

Niroo Gupta

series ordinal

2

1 reference

3 November 2017

Margaret McAlary

series ordinal

3

1 reference

3 November 2017

Angel Fowler-Taylor

series ordinal

4

1 reference

3 November 2017

1 August 2003

1 reference

Annals of Allergy, Asthma & Immunology

3 November 2017

1 reference

3 November 2017

91

1 reference

3 November 2017

2

1 reference

3 November 2017

182-188

1 reference

Prevalence, impact, and trends in childhood disability due to asthma

3 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Asthma and wheezing in the first six years of life. The Group Health Medical Associates

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Therapeutic potential of anti-IgE antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

The pharmacological basis of anti-IgE therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

Standardization and stability of immunoglobulin E (IgE)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962175-8

1 reference

7 January 2021

10.1016/S1081-1206(10)62175-8

Identifiers

DOI

1 reference

3 November 2017

1 reference